Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.15 -1.8%	$9.39	$3.75 ▼ $11.54	$134.13M	2.71	65,977 shs	28,746 shs
ALLO Allogene Therapeutics	$1.12 -0.9%	$1.20	$0.86 ▼ $3.78	$250.73M	0.36	4.35 million shs	3.28 million shs
AMLX Amylyx Pharmaceuticals	$9.98 +6.4%	$7.93	$2.08 ▼ $9.99	$836.39M	-0.44	1.14 million shs	2.50 million shs
BNTC Benitec Biopharma	$13.77 +4.0%	$12.32	$8.06 ▼ $17.15	$347.56M	0.43	37,857 shs	47,252 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	-1.81%	+2.77%	-9.94%	-14.84%	+814,999,900.00%
ALLO Allogene Therapeutics	-0.88%	-3.45%	+3.70%	-13.18%	-57.41%
AMLX Amylyx Pharmaceuticals	+6.40%	+8.95%	+29.27%	+102.85%	+349.55%
BNTC Benitec Biopharma	+4.00%	+7.92%	+25.64%	-11.05%	+49.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACOG Alpha Cognition	2.4687 of 5 stars	3.5	0.0	3.0	2.5	0.0
ALLO Allogene Therapeutics	2.1851 of 5 stars	3.4	1.0	2.0	2.5	0.6
AMLX Amylyx Pharmaceuticals	2.6902 of 5 stars	3.5	1.0	3.3	2.5	0.6
BNTC Benitec Biopharma	1.7198 of 5 stars	3.6	1.0	2.7	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$20.00	145.40% Upside
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	653.97% Upside
AMLX Amylyx Pharmaceuticals	3.00	Buy	$12.25	22.75% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	88.82% Upside

Current Analyst Ratings Breakdown

Latest ACOG, ALLO, AMLX, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	AMLX Amylyx Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	$2.59 per share	N/A
ALLO Allogene Therapeutics	$20K	12,425.28	N/A	N/A	$1.55 per share	0.72
AMLX Amylyx Pharmaceuticals	$87.37M	10.19	N/A	N/A	$1.88 per share	5.31
BNTC Benitec Biopharma	$80K	4,518.28	N/A	N/A	$4.68 per share	2.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$14.64M	-$1.60	N/A	∞	N/A	N/A	-80.16%	-60.95%	11/13/2025 (Estimated)
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
AMLX Amylyx Pharmaceuticals	-$301.74M	-$2.50	N/A	N/A	N/A	N/A	-82.48%	-70.15%	11/6/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)

Latest ACOG, ALLO, AMLX, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2025	Q4 2025	BNTC Benitec Biopharma	-$0.24	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	ACOG Alpha Cognition	-$0.46	-$0.65	-$0.19	-$0.65	$2.32 million	$1.66 million
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	17.14	16.83
ALLO Allogene Therapeutics	N/A	8.92	8.92
AMLX Amylyx Pharmaceuticals	N/A	8.72	8.72
BNTC Benitec Biopharma	0.01	14.80	14.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
ALLO Allogene Therapeutics	83.63%
AMLX Amylyx Pharmaceuticals	95.84%
BNTC Benitec Biopharma	52.19%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	14.00%
ALLO Allogene Therapeutics	13.20%
AMLX Amylyx Pharmaceuticals	12.30%
BNTC Benitec Biopharma	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	N/A	16.16 million	13.90 million	N/A
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
AMLX Amylyx Pharmaceuticals	200	89.17 million	78.20 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data

ACOG, ALLO, AMLX, and BNTC Headlines

Recent News About These Companies

Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Below Fifty Day Moving Average - Should You Sell?

August 23, 2025 | marketbeat.com

We're Interested To See How Benitec Biopharma (NASDAQ:BNTC) Uses Its Cash Hoard To Grow

August 17, 2025 | finance.yahoo.com

Informed Momentum Co LLC Buys Shares of 39,330 Benitec Biopharma Limited (NASDAQ:BNTC)

August 14, 2025 | marketbeat.com

Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Rating of "Buy" from Brokerages

August 12, 2025 | marketbeat.com

Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Below 50 Day Moving Average - What's Next?

August 7, 2025 | marketbeat.com

Benitec Biopharma Inc.: Benitec Biopharma Provides Operational Updates

July 10, 2025 | finanznachrichten.de

Benitec Biopharma Provides Operational Updates

July 9, 2025 | taiwannews.com.twT

Benitec Biopharma Ltd ADR News (BNTC) - Investing.com

July 2, 2025 | investing.com

Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable

June 16, 2025 | zacks.com

Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

June 5, 2025 | zacks.com

Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?

June 4, 2025 | zacks.com

Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why

May 29, 2025 | zacks.com

Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet

May 20, 2025 | zacks.com

Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?

May 19, 2025 | zacks.com

Benitec Biopharma Releases Third Quarter 2025 Financial Results

May 14, 2025 | manilatimes.netM

Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why

May 5, 2025 | zacks.com

Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?

May 2, 2025 | zacks.com

Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade

April 25, 2025 | zacks.com

What Makes Benitec Biopharma (BNTC) a New Buy Stock

April 23, 2025 | zacks.com

Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer

April 15, 2025 | seekingalpha.com

Benitec Biopharma price target raised to $20 from $18 at Citizens JMP

April 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACOG, ALLO, AMLX, and BNTC Company Descriptions

Alpha Cognition NASDAQ:ACOG

$8.15 -0.15 (-1.81%)

As of 09/2/2025 03:59 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Allogene Therapeutics NASDAQ:ALLO

$1.12 -0.01 (-0.88%)

Closing price 09/2/2025 04:00 PM Eastern

Extended Trading

$1.18 +0.05 (+4.91%)

As of 06:13 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Amylyx Pharmaceuticals NASDAQ:AMLX

$9.98 +0.60 (+6.40%)

Closing price 09/2/2025 04:00 PM Eastern

Extended Trading

$9.77 -0.21 (-2.10%)

As of 04:01 AM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Benitec Biopharma NASDAQ:BNTC

$13.77 +0.53 (+4.00%)

Closing price 09/2/2025 04:00 PM Eastern

Extended Trading

$13.70 -0.07 (-0.51%)

As of 09/2/2025 04:20 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time